Drug Trial Radar · NCT07616739
Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Sep 10, 2026
Primary completion
Oct 15, 2028
Study completion Oct 15, 2028
Sponsor
- Lead sponsor
- Fundación HuéspedAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ViiV Healthcare
- First posted
- Jun 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Protocol Number: FH-94 Study Objetives: Primary: * To evaluate the virological response to Dolutegravir/Lamivudine in naive pregnant women with HIV who are starting antiretroviral therapy and vertical transmission in exposed neonates. Secondary: * To evaluate the incidence of maternal adverse events. * To evaluate perinatal outcomes at delivery. * To evaluate maximum virological suppression at delivery. * To evaluate the incidence of changes in body weight exceeding what is expected for gestation. * To evaluate the immune response based on changes in CD4, CD8, and CD4/CD8 ratio values during pregnancy. * Assess baseline resistance and the development of resistance to virological failure to integrase inhibitors and INTRs during treatment with DTG+3TC or DTG+TDF/XTC or DTG+TAF/FTC. * To evaluate the incidence of HIV infection in children that breastfeed. * To evaluate safety outcomes and virological response of DTG+3TC compared to DTG+TDF/XTC or DTG+TAF/FTC. Exploratory: * To explore the non-inferiority of DTG+3TC therapy compared to DTG+TDF/XTC or DTG+TAF/FTC treatment. * To evaluate the frequency of antiretroviral therapy withdrawal or modification before delivery.
Conditions
- HIV-1-infection
Interventions
Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]Drug
1 pill QD
TDF/XTC or TAF/FTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)Drug
1 pill of each QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the virological response to Dolutegravir/Lamivudine in pregnant women with HIV who are starting antiretroviral therapy and vertical transmission in exposed neonatesTime frame: From enrollment to the end of treatment at 6 months after delivery
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Hospital General de Agudos Dr. Cosme Argerich
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Sanatorio Güemes
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Hospital de Agudos J.A. Fernandez
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Hospital Nacional Profesor Alejandro Posadas
El Palomar, Buenos Aires, Argentina · Not yet recruiting
Hospital de Agudos Paroissien
Isidro Casanova, Buenos Aires, Argentina · Not yet recruiting
RDSS - Ricardo Sobhie Diaz & Cia Solucoes Cientificas Ltda - Ricardo Diaz Scientific Solution
São Paulo, Brazil · Not yet recruiting
Fundação Bahiana de Infectologia
Salvador, Estado de Bahia, Brazil · Not yet recruiting
Complexo do Hospital de Clínicas da UFPR/Ebserh
Curitiba, Pernambuco, Brazil · Not yet recruiting
Hospital Geral de Nova Iguaçu
Nova Iguaçu, Rio de Janeiro, Brazil · Not yet recruiting
Universidade Federal do Rio Grande do Norte
Natal, Rio Grande do Norte, Brazil · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.